Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Upgraded by StockNews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other research firms also recently weighed in on ATNM. Maxim Group upped their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Cantor Fitzgerald restated an “overweight” rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday, April 29th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.72.

Actinium Pharmaceuticals Price Performance

NYSEAMERICAN:ATNM opened at $8.84 on Friday. Actinium Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $9.86. The stock has a market cap of $263.26 million, a price-to-earnings ratio of -5.17 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million during the quarter. Equities research analysts expect that Actinium Pharmaceuticals will post -1.48 earnings per share for the current year.

Institutional Trading of Actinium Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ATNM. Creative Financial Designs Inc. ADV raised its stake in Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares during the last quarter. Sanders Morris Harris LLC acquired a new position in shares of Actinium Pharmaceuticals in the first quarter valued at about $78,000. Finally, Brandywine Global Investment Management LLC purchased a new position in shares of Actinium Pharmaceuticals in the third quarter worth about $1,033,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.